Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company

GlobeNewswireMay 14 06:00

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersAclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) s

BenzingaApr 25 11:31

Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8μL spray per eye)Also announces upcoming ARVO presen

BenzingaApr 25 06:36

Eyenovia Shares Fall More Than 14% After Company Says It Is Exploring Sale

By Emon Reiser Shares of Eyenovia were on the decline after the commercial-stage ophthalmic company said it was exploring strategic options, including a potential sale. The stock decreased 14.6% to

WSJApr 8 13:38

Eyenovia Explores Options, Including Potential Sale

By Colin Kellaher Eyenovia on Monday said it is exploring strategic options, including a potential sale of the ophthalmic company. In addition to a sale, Eyenovia, said it plans to consider a range

WSJApr 8 06:21

Eyenovia Initiates Process To Explore Strategic Alternatives To Maximize Shareholder Value

The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine). In conjunction with the strategic process and f

BenzingaApr 8 06:02